12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SNS01-T: Phase Ib/IIa amended

Senesco said it amended an open-label, dose-escalation, U.S. Phase Ib/IIa trial of twice-weekly IV SNS01-T for 6 weeks in patients with relapsed or refractory MM to include patients with DLBCL and MCL. The...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >